Insights

Read our independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Our work is reader-supported. Sign up to our free or paid plans here.

Subcribe to Pα+
Visit the Pα+ Dashboard

The latest

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin Becomes Helus

January 8, 2026

Gilgamesh Prints Positive Topline from Phase 2a Study of NMDA Receptor Agonist for MDD • FDA Lifts Hold on GH Research’s Inhaled 5-MeO-DMT IND After More than Two Years • Cybin Rebrands to Helus Pharma, Lists on Nasdaq • Compass Details PTSD Trial Design, Reaffirms TRD Launch Readiness ‘By End of Year’ • Emory Registers Trial of MDMA-Assisted Massed Exposure Therapy in Active Duty Troops • Filings Provide a Look at Psychedelics Nonprofits’ Finances • and more…

2025 Year in Review: 10 Standout Stories in Psychedelics

January 2, 2026

Psychedelic Alpha looks back on 2025, highlighting the ten stories that defined a pivotal year for psychedelic drug development, policy, and access, as well as key interviews and reflections from across the field. All Pα+ stories featured in this Top 10 are available to read, for free, throughout January 2026.

2025 Year in Review: Psychedelics in 2025 (Video)

December 23, 2025

In the first of a three-part series, Psychedelic Alpha’s Josh Hardman takes a look back at 2025 via a narrated presentation. In this hour-long video, Hardman reviews developments across psychedelic drug development, policy, industry, and access programs in the year gone by.

Pα+ Psychedelic Bulletin #216: Australia’s Psychedelics-for-Veterans Funding; New Mexico Targets 2026 Medical Psilocybin Launch; Radial Scores $50M; Otsuka’s “Novel Serotonergic Agonists”; Psilocybin Accelerates Brain Tumour Growth in Mice; Texas’ $50M Ibogaine Study Consortium

December 17, 2025

Australia’s Department of Veterans’ Affairs Explains World-First Funding Model for Psychedelic-Assisted Psychotherapy • New Mexico Targets December 2026 for Medical Psilocybin Launch • Otsuka Publicly Signals Work on “Psychedelic-Inspired” CNS Compounds • Psilocybin Promotes Growth of Existing Brain Tumours in Mice, Preprint Study Reports • Interview: Radial Scores $50M, Eyes Interventional Psychiatry—and Psychedelics • State of Texas Awards $50M to Ibogaine Trials • Interview: Fireside Project Unveils AI Chatbot Aimed at Training Psychedelic Practitioners • Czech Medical Body Drafts Guidelines for Psilocybin Therapy, Targets 2026 Launch • and more…

Load more

The Library

Through our years of reporting we have covered many of the topics we believe to be important to the present and future of the psychedelics space, broadly defined. However, much of this commentary is scattered across Bulletins, deep dives, special reports and year-end reviews.

The Library provides digestible explainers on salient topics across psychedelic drug development, policy and business: from basic explainers such as “what is psychedelic-assisted therapy?” through to more complex matters such as REMS programs and bifurcated scheduling.

It’s exclusively available to our Pα+ subscribers, with new content added regularly.

Subcribe to Pα+

Pα+ Library: Bifurcated Scheduling

December 6, 2023

Pα+ Library: we introduce some of the key concepts in the matter of bifurcated scheduling; a process by which an approved drug product may be placed in a different schedule to the substance itself. As we discuss in this piece, this could have significant repercussions for psychedelic research, legality, and even taxes.

Pα+ Library: Psychedelic REMS

November 15, 2023

Pα+ Library: we sketch out what a psychedelic REMS might look like, highlighting how these programs could have an outsized impact on the post-approval delivery and accessibility of these treatments.

The Psychedelic Practitioner

The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.

The Psychedelic Practitioner Issue 2: Preparation

December 11, 2025

The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments. In this Issue, we take a deep dive into the science and practice of psychedelic preparation through interviews, research reviews, and practitioner perspectives.

The Psychedelic Practitioner: Issue 1

October 9, 2025

The Psychedelic Practitioner by Psychedelic Alpha is a new publication designed specifically for therapists, clinicians, facilitators, and other professionals working with—or preparing to work with—psychedelic therapies and related treatments.

The Psychedelic News Feed Archives

Archived versions of our Psychedelic News Feed.

Load more